The eIF4E pathway is a target for cancer therapy with drugs that either inhibit eIF4E activity indirectly (mTOR inhibitors that reduce 4E-BP1 phosphorylation thereby inhibiting eIF4E (Smolewski, 2006)), or directly (by binding to/reducing expression of eIF4E (Graff et al, 2008)). This evidence concerns the gene MTOR and cancer.